Media headlines about InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) have trended somewhat positive this week, Accern Sentiment reports. Accern scores the sentiment of news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. InVivo Therapeutics Holdings Corp. earned a daily sentiment score of 0.14 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 48.6351981384084 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
NVIV has been the topic of several recent research reports. Raymond James Financial, Inc. lowered shares of InVivo Therapeutics Holdings Corp. from an “outperform” rating to a “market perform” rating in a research report on Monday, July 31st. ValuEngine lowered shares of InVivo Therapeutics Holdings Corp. from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st.
InVivo Therapeutics Holdings Corp. (NASDAQ NVIV) traded up $0.02 during trading on Tuesday, hitting $1.27. 125,200 shares of the company traded hands, compared to its average volume of 267,961. InVivo Therapeutics Holdings Corp. has a 1-year low of $1.10 and a 1-year high of $5.90.
InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) last released its quarterly earnings data on Monday, October 30th. The biotechnology company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.06).
ILLEGAL ACTIVITY NOTICE: This report was first posted by Transcript Daily and is the property of of Transcript Daily. If you are accessing this report on another publication, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this report can be read at https://transcriptdaily.com/2017/11/15/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-invivo-therapeutics-holdings-corp-nviv-share-price.html.
InVivo Therapeutics Holdings Corp. Company Profile
InVivo Therapeutics Holdings Corp., formerly Design Source, Inc, is a research and clinical-stage biomaterials and biotechnology company. The Company is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Company’s approach to treating acute SCIs is based on its investigational Neuro Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury.
Receive News & Ratings for InVivo Therapeutics Holdings Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVivo Therapeutics Holdings Corp. and related companies with MarketBeat.com's FREE daily email newsletter.